Brainstorm Cell Therapeutics (BCLI) Competitors $0.66 +0.01 (+1.77%) As of 10/20/2025 02:37 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. DARE, ENLV, CVKD, PASG, LPTX, PMN, LNAI, CASI, MIRA, and TAOXShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Dare Bioscience (DARE), Enlivex Therapeutics (ENLV), Cadrenal Therapeutics (CVKD), Passage Bio (PASG), Leap Therapeutics (LPTX), Promis Neurosciences (PMN), Lunai Bioworks (LNAI), CASI Pharmaceuticals (CASI), MIRA Pharmaceuticals (MIRA), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Its Competitors Dare Bioscience Enlivex Therapeutics Cadrenal Therapeutics Passage Bio Leap Therapeutics Promis Neurosciences Lunai Bioworks CASI Pharmaceuticals MIRA Pharmaceuticals Synaptogenix Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability. Which has more volatility & risk, BCLI or DARE? Brainstorm Cell Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Is BCLI or DARE more profitable? Company Net Margins Return on Equity Return on Assets Brainstorm Cell TherapeuticsN/A N/A -519.50% Dare Bioscience N/A N/A -103.70% Does the media favor BCLI or DARE? In the previous week, Dare Bioscience's average media sentiment score of 1.73 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Overall Sentiment Brainstorm Cell Therapeutics Neutral Dare Bioscience Very Positive Which has better earnings and valuation, BCLI or DARE? Dare Bioscience has higher revenue and earnings than Brainstorm Cell Therapeutics. Dare Bioscience is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.10-0.21Dare Bioscience$10K2,763.40-$4.05M-$2.14-0.96 Do analysts prefer BCLI or DARE? Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 387.80%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Brainstorm Cell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders believe in BCLI or DARE? 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 4.8% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryDare Bioscience beats Brainstorm Cell Therapeutics on 9 of the 12 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.30M$3.46B$6.14B$10.56BDividend YieldN/A2.27%5.72%4.84%P/E Ratio-0.2023.3929.4727.34Price / SalesN/A486.24588.64242.12Price / CashN/A45.2825.8230.35Price / Book-0.4910.6112.526.69Net Income-$11.62M-$52.56M$3.32B$276.46M7 Day Performance-5.50%3.95%1.81%-0.08%1 Month Performance-5.43%16.10%8.80%3.93%1 Year Performance-69.79%15.08%64.28%33.89% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics1.3661 of 5 stars$0.66+1.8%N/A-70.6%$7.30MN/A-0.2040DAREDare Bioscience2.5512 of 5 stars$2.12flat$10.00+371.7%-45.0%$28.58M$10K-0.9930Positive NewsENLVEnlivex Therapeutics2.7104 of 5 stars$1.10-4.3%$10.00+809.1%-30.3%$27.94MN/A-1.9070CVKDCadrenal Therapeutics2.9311 of 5 stars$13.99+2.7%$32.00+128.7%-25.2%$27.88MN/A-1.584PASGPassage Bio3.1125 of 5 stars$8.69+2.6%$75.67+770.7%-26.3%$26.93MN/A-0.48130News CoverageLPTXLeap Therapeutics2.8682 of 5 stars$0.60-5.5%$3.38+459.6%-80.5%$26.46MN/A-0.3840News CoverageAnalyst DowngradeShort Interest ↓Gap UpPMNPromis Neurosciences3.6512 of 5 stars$0.48-2.0%$4.33+802.8%-54.6%$26.37MN/A-2.295Positive NewsShort Interest ↓LNAILunai BioworksN/A$1.16+2.7%N/AN/A$26.19MN/A-0.1520Gap UpCASICASI Pharmaceuticals3.5966 of 5 stars$1.89-4.5%$4.00+111.6%-68.1%$24.35M$28.54M-0.65180Gap DownMIRAMIRA Pharmaceuticals0.3931 of 5 stars$1.29+2.0%N/A+37.3%$24.03MN/A-2.622TAOXSynaptogenix0.0783 of 5 stars$9.54+38.5%N/AN/A$24.03MN/A-0.474News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies DARE Competitors ENLV Competitors CVKD Competitors PASG Competitors LPTX Competitors PMN Competitors LNAI Competitors CASI Competitors MIRA Competitors TAOX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
